Angiogenesis is a mechanism necessary for the expansion and progression of tumors. Understanding the mechanism of angiogenesis in PMP allows us to select therapeutic targets that may be used in place of or with existing anti-angiogenic therapy (Bevacizumab). We have shown that CEA a common protein produced by PMP interacts with immune cells in the peritoneal cavity and produces specific cytokines that are pro-angiogenic. The interaction of CEA with these cell may be an alternate target to Vascular Endothelial Cell Growth Factor (VEGF) and may be effective in reducing angiogenesis.